Delivery Order SPE2DB24D2100-SPE2DB26FBAKK
- Not listed
- The Defense Logistics Agency awarded a $40,930.24 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Dupixent 300 mg/2 mL pens (2 mL) with completion targeted for September 29, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery...
- The Defense Logistics Agency awarded a $50,642.59 delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Dupixent 300 mg/2 ml pens (2 ml units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 22, 2025. The contract is performed from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $17,843.46 delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 26, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office...
- The Defense Logistics Agency awarded a $10,317.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This is a non-set-aside contract, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving military and veteran...
- The Defense Logistics Agency awarded a $34,661.18 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting open competition among qualified vendors. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $21,536.39 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on April 24, 2025, with an ultimate completion date of April 25, 2025. The contract employs firm fixed price pricing and was competitively awarded without a set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location....
- The Defense Logistics Agency awarded a delivery order valued at $17,370.55 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on September 18, 2025, with an ultimate completion date of September 19, 2025. This is a firm fixed-price, non-set-aside contract executed under an Indefinite Delivery Contract vehicle. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through...
- The Defense Logistics Agency awarded a delivery order valued at $17,561.86 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on October 22, 2025, with an ultimate completion date of October 23, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions such as atopic...
- The Defense Logistics Agency awarded a $31,497.66 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by June 3, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat various allergic and inflammatory conditions, including atopic...
- The Defense Logistics Agency awarded a $25,054.58 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitive, non-set-aside contract represents a firm fixed price delivery order with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat conditions including atopic dermatitis,...
- SPE2DB24D2100Indefinite Delivery Contract
- SPE2DB24D2100-SPE2DB26FBAKKDelivery Order
The Defense Logistics Agency awarded a $28,714.55 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pens. The contract represents a firm fixed-price delivery order with no set-aside designation, completed competitively. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 23, 2025. This award is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply agreement valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills critical medical procurement needs for military and veteran healthcare systems through its extensive federal contract portfolio. The company supplies a comprehensive range of pharmaceutical products across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, vaccines, and medical devices. Dupixent is a biologic treatment used for conditions including atopic dermatitis and asthma, representing the type of specialized pharmaceutical support that AmerisourceBergen provides to the Defense Health Agency and other federal healthcare systems through its DLA prime vendor arrangement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.7k | 10/22/25 |